Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate and Methazolamide for Essential Tremor
NCT06312800Phase 2Withdrawn
- Sponsor
- Henry Ford Health
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acamprosate, methazolamide in essential tremor (ET), sponsored by Henry Ford Health. Planned start Mar 2016; status: withdrawn.
02
Drugs
acamprosatemethazolamide
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT06312800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312800.